What is the recommended approach for performing percutaneous coronary intervention (PCI) in a patient who is on oral anticoagulation (warfarin or a direct oral anticoagulant)?

PCI in Patients on Oral Anticoagulation

For patients on oral anticoagulation requiring PCI, the approach depends critically on urgency: proceed immediately without delay for emergent cases (STEMI/high-risk NSTEMI), hold anticoagulation for specific time periods based on agent and renal function for elective cases, and use radial access with unfractionated heparin during the procedure, then resume a DOAC (preferred over warfarin) within 24 hours post-PCI combined with clopidogrel as dual therapy (not triple therapy for most patients). 1

Preprocedural Management

Emergency PCI (STEMI or High-Risk NSTEMI)

• Stop anticoagulation immediately and proceed to PCI without delay 1
• Do not wait for anticoagulation to wear off
• Note: Activated clotting time is unreliable for monitoring DOAC effect 1
• Administer aspirin 162-325 mg and clopidogrel 600 mg loading dose 1

Elective or Urgent PCI (Can Be Safely Deferred)

For patients on warfarin:

• Defer PCI until INR ≤2.0 (some centers use ≤1.5, particularly for femoral access) 1
• For NSTE-ACS patients, consider bridging with unfractionated heparin or LMWH as INR decreases 1
• Important caveat: Bridging is NOT recommended for DOAC patients 1

For patients on DOACs - hold based on renal function and access site: 1

Transradial approach (preferred):

• Apixaban, edoxaban, rivaroxaban: 24 hours if CrCl ≥30 mL/min; 36 hours if CrCl 15-29 mL/min
• Dabigatran: 24 hours if CrCl ≥80; 36 hours if CrCl 50-79; 48 hours if CrCl 30-49; 72 hours if CrCl 15-29 mL/min

Transfemoral approach (if radial not feasible):

• Apixaban, edoxaban, rivaroxaban: 48 hours if CrCl ≥30 mL/min; 72 hours if CrCl <29 mL/min
• Dabigatran: 48 hours if CrCl >80; 72 hours if CrCl 50-79; 96 hours if CrCl 30-49; 120 hours if CrCl 15-29 mL/min

This approach is supported by the PAUSE study demonstrating low rates of bleeding and thromboembolism with pharmacokinetic-based interruption strategies 1

Procedural Management

Access site selection:

• Strongly prefer radial access to minimize bleeding risk, particularly when anticoagulation cannot be fully interrupted 1
• Recent observational data suggest uninterrupted DOAC with radial access may be safe in selected low-risk cases 2, 3, though guideline-based interruption remains standard practice
• Use vascular closure devices if femoral access required 1

Intraprocedural anticoagulation:

• Use unfractionated heparin, LMWH, or bivalirudin per standard dosing guidelines 1
• All three agents have Class I recommendations 1
• Consider glycoprotein IIb/IIIa inhibitors or cangrelor only for high-risk anatomic features (e.g., fresh thrombus), recognizing increased bleeding risk 1

Stent selection:

• Use newest-generation drug-eluting stents even in high bleeding risk patients 1
• Avoid bare metal stents 1

Post-Procedural Management

Anticoagulation Resumption

Timing:

• Resume anticoagulation within 24 hours post-PCI in most patients (can be as early as evening of procedure day) 1
• Delay 48-72 hours only in high bleeding risk patients 1
• Assess access site hemostasis, bleeding history, body habitus, and coagulation abnormalities before resuming 1

Agent selection:

• Strongly prefer DOAC over warfarin post-PCI due to lower major bleeding, fatal bleeding, and intracranial hemorrhage rates 1
• If patient was on DOAC pre-PCI, continue same DOAC 1
• If patient was on warfarin pre-PCI, switch to DOAC if eligible 1
• Only continue warfarin if DOAC contraindicated or patient had excellent INR control pre-PCI 1

DOAC dosing considerations:

• Most DOACs: use standard FDA-approved doses for atrial fibrillation 1
• Rivaroxaban exception: Use 15 mg daily (CrCl >50 mL/min) or 10 mg daily (CrCl 30-50 mL/min) while on antiplatelet therapy, then increase to 20 mg or 15 mg respectively after antiplatelet cessation 1
• Adjust all DOAC doses based on post-PCI renal function 1

Antiplatelet Therapy Strategy

Default approach - Dual Therapy (OAC + P2Y12 inhibitor): 1, 4

• Clopidogrel is strongly preferred P2Y12 inhibitor (not prasugrel or ticagrelor in most cases) 1
• Discontinue aspirin at or before hospital discharge in most patients 1, 4
• This represents a major shift from historical triple therapy

Duration of dual therapy:

• ACS patients: Continue clopidogrel for 12 months 1
• Stable ischemic heart disease: Continue clopidogrel for 6 months 1
• After completing dual therapy duration, continue OAC monotherapy indefinitely 4

Triple therapy (OAC + aspirin + clopidogrel) - limited role:

• Consider aspirin 81 mg for up to 30 days only in patients with both high thrombotic risk AND low bleeding risk 1, 4
• Aspirin may be continued until INR therapeutic in warfarin patients not receiving bridging 1
• Most patients should NOT receive triple therapy beyond hospitalization 4

Special Considerations for Warfarin Patients

If warfarin used post-PCI (when DOAC not feasible):

• Resume previous therapeutic dose 1
• Target INR 2.0-2.5 (lower end of therapeutic range) 1
• Bridging with parenteral anticoagulation only for high thromboembolic risk subset 1
• Consider continuing aspirin 81 mg with clopidogrel until INR therapeutic if not bridging 1

Common Pitfalls to Avoid

1. Do not routinely use triple therapy - bleeding risk outweighs benefit in most patients 4
2. Do not bridge DOAC patients with LMWH - similar pharmacokinetics make this unnecessary and increase bleeding 1
3. Do not use prasugrel or ticagrelor as default P2Y12 inhibitor - clopidogrel preferred due to lower bleeding risk 1
4. Do not forget to uptitrate rivaroxaban dose after stopping antiplatelet therapy 1
5. Do not continue aspirin long-term - stop at discharge or within 30 days maximum 1, 4
6. Do not use femoral access routinely - radial approach significantly reduces bleeding 1

Recent observational data suggest that interrupting anticoagulation is safe with very low thromboembolic rates (0.1-0.2%), while bridging therapy independently increases bleeding risk (OR 2.39) 5. Uninterrupted DOAC with radial access may be reasonable in selected low-risk cases 2, 3, though this remains off-guideline and requires careful patient selection.